Bedside Snapshot

Propranolol is a nonselective beta-blocker (beta-1 and beta-2) used IV mostly for short-term control of supraventricular tachyarrhythmias and hyperadrenergic states (e.g., thyrotoxic tachycardia) in monitored settings.

  • Characteristics: Lipophilic, crosses the blood-brain barrier, and has no alpha-blocking activity. Compared with labetalol or esmolol, propranolol is less commonly chosen for hypertensive emergencies but is still useful for rate control in SVT/AF or thyrotoxicosis when IV beta-blockade is needed.
  • Typical adult IV dosing: 1 mg IV over at least 1 minute; may repeat every 2 minutes to a total of 3 mg. Once effect achieved (or 3 mg given), no further IV propranolol should be given for at least 4 hours.
  • Onset (IV): Within minutes; distribution half-life ~5–10 minutes. Duration of clinically relevant beta-blockade is usually 2–4 hours after a small bolus; elimination half-life ~2–6 hours.
  • Oral use: Widely used for chronic indications (angina, post-MI, migraine prophylaxis, portal hypertension/varices, essential tremor, anxiety). In the ED/ICU, IV use requires continuous ECG and BP monitoring.
Brand & Generic Names
  • Generic Name: Propranolol hydrochloride
  • Brand Names: Inderal, Inderal LA, various generics; IV propranolol 1 mg/mL vials/ampules
Medication Class

Nonselective beta-adrenergic blocker (beta-1 and beta-2); no intrinsic sympathomimetic activity

Pharmacology

Mechanism of Action:

  • Competitively blocks beta-1 and beta-2 adrenergic receptors, reducing chronotropy, inotropy, and AV nodal conduction (beta-1) and attenuating beta-2 mediated vasodilation and bronchodilation
  • Reduces heart rate, myocardial contractility, and myocardial oxygen demand; prolongs AV nodal conduction time, which slows ventricular response in supraventricular tachyarrhythmias
  • Lack of intrinsic sympathomimetic activity means a relatively pure beta-blocking effect; no alpha blockade, so BP reduction is via decreased cardiac output and suppression of renin rather than vasodilation
  • Lipophilicity allows CNS penetration, which may contribute to effects on tremor, anxiety, and migraine, but also to CNS adverse effects (fatigue, depression, vivid dreams) with chronic use

Pharmacokinetics:

  • IV concentration: Usually 1 mg/mL propranolol hydrochloride solution
  • Onset (IV): Effects on heart rate and BP occur within minutes of administration
  • Distribution: Highly lipophilic with extensive tissue binding; distribution half-life ~5–10 minutes. Protein binding ~90–95%. Volume of distribution ~4–5 L/kg
  • Metabolism: Extensive first-pass and systemic hepatic metabolism to multiple inactive and active metabolites
  • Elimination half-life: Approximately 2–6 hours after IV dosing in adults with normal hepatic function; prolonged in hepatic impairment or cirrhosis
  • Elimination: Primarily via hepatic metabolism with urinary excretion of metabolites; dose adjustments are mainly guided by clinical response and hepatic function rather than renal function
Indications
  • Supraventricular tachycardia (SVT): Short-term treatment, including atrial flutter and certain atrial tachyarrhythmias, particularly when other first-line agents are ineffective or contraindicated
  • Atrial fibrillation/flutter rate control: Usually when other AV nodal blockers are unsuitable or as adjunct therapy
  • Thyrotoxic crisis/thyroid storm: Adjunctive therapy to control tachycardia and reduce peripheral conversion of T4 to T3 (though oral or NG dosing is often preferred if feasible)
  • Peri-anesthesia/perioperative: Control of hyperadrenergic tachycardia and hypertension in selected patients
  • Pediatric arrhythmias: Specialist-driven, often weight-based dosing (beyond scope of this adult-focused reference)
Dosing & Administration

Available Forms:

  • IV injection: 1 mg/mL in 1 mL ampules or vials for slow IV administration or dilution
  • Oral immediate-release tablets: commonly 10 mg, 20 mg, 40 mg, 60 mg, 80 mg
  • Oral extended-release capsules (LA/XL): commonly 60 mg, 80 mg, 120 mg, 160 mg

Standard Adult Dosing:

Indication Dose & Route Frequency / Titration Notes
Supraventricular tachycardia / atrial arrhythmias (acute rate control) 1 mg IV over at least 1 minute May repeat q2 minutes up to total 3 mg After 3 mg or adequate effect, hold further IV doses for at least 4 hours
Thyrotoxic crisis (when IV route needed) 1 mg IV over 1 minute Repeat q2 minutes up to 3 mg, then transition to oral/NG dosing (e.g., 20–40 mg PO q6h) as tolerated Use with extreme caution in decompensated HF or hypotension; esmolol is often preferred
Perioperative hyperadrenergic tachycardia (selected cases) 0.5–1 mg IV over 1 minute Repeat q2–5 minutes to max total 3–5 mg as needed Use only with continuous ECG/BP monitoring and resuscitation capabilities
Continuous infusion (less common; specialist use) 2–3 mg/hour IV infusion Titrate to heart rate/BP targets More often, short boluses are used rather than continuous infusion
Oral step-down for arrhythmias 10–30 mg PO 3–4 times daily (IR) Titrate to 40–160 mg/day for arrhythmia control Adjust dose based on HR/BP, comorbidities, and chronic indications
Administration Notes: IV propranolol should be given slowly (not exceeding 1 mg/min) with continuous ECG and blood pressure monitoring. Allow time after each dose (at least 2 minutes) to assess full effect before redosing, especially in patients with reduced cardiac output or slow circulation.
Contraindications

Absolute Contraindications:

  • Cardiogenic shock or overt decompensated heart failure (unless tachyarrhythmia-driven and managed by specialists)
  • Sinus bradycardia, greater than first-degree heart block (unless paced), or sick sinus syndrome
  • Bronchial asthma or significant bronchospastic disease
  • Hypersensitivity to propranolol or other beta-blockers

Major Precautions:

  • COPD or reactive airway disease: Even small doses can provoke bronchospasm in susceptible patients
  • Diabetes mellitus: May mask hypoglycemic symptoms (tachycardia, tremor) and blunt counter-regulatory responses
  • Peripheral vascular disease and Raynaud phenomenon: Can exacerbate vasospasm and ischemia
  • Depression and psychiatric disorders: CNS penetration may worsen mood symptoms in some patients
  • Hepatic impairment: Reduced clearance and prolonged half-life; titrate doses cautiously
Bronchospasm Risk: Because propranolol is nonselective (blocks beta-2 receptors), it can cause severe bronchospasm in patients with asthma or reactive airway disease. Avoid use in these patients.
Adverse Effects

Common:

  • Bradycardia, hypotension, fatigue
  • Dizziness, lightheadedness
  • Cold extremities, exercise intolerance
  • Gastrointestinal upset (nausea, diarrhea)

Serious:

  • Symptomatic bradycardia, high-grade AV block, asystole
  • Acute decompensated heart failure or cardiogenic shock
  • Bronchospasm, especially in asthma
  • Severe hypotension
  • Masking of hypoglycemia and prolonged hypoglycemic episodes in insulin-treated diabetics
Special Populations

Hepatic Impairment:

  • Reduced clearance and prolonged half-life in hepatic impairment or cirrhosis
  • Titrate doses cautiously and monitor closely for excessive beta-blockade
  • Consider lower initial doses and longer intervals between doses

Renal Impairment:

  • Dose adjustments are mainly guided by clinical response and hepatic function rather than renal function
  • Monitor carefully as these patients may have multiple comorbidities

Diabetes:

  • May mask hypoglycemic symptoms (tachycardia, tremor) and blunt counter-regulatory responses
  • Use with caution and ensure close blood glucose monitoring, particularly in insulin-treated patients

Oral to IV Conversion:

  • When transitioning from IV to oral propranolol, remember that oral bioavailability is lower and variable due to first-pass metabolism
  • Start with modest oral doses and titrate to effect
Monitoring

Clinical Monitoring:

  • Continuous ECG and blood pressure monitoring during IV dosing and in unstable patients
  • Heart rate and rhythm for bradycardia, AV block, or new arrhythmias
  • Signs and symptoms of heart failure (dyspnea, edema, rising BNP or lactate)
  • Respiratory status, especially in patients with any bronchospastic history

Laboratory Monitoring:

  • Blood glucose in diabetics receiving IV beta-blockade, particularly if insulin or sulfonylureas are in use
  • Liver function tests if prolonged or high-dose therapy is anticipated
Clinical Pearls
Not First-Line for Hypertensive Emergencies: Because propranolol is nonselective and lacks alpha blockade, it is not the first-line agent for hypertensive emergencies; reserve IV use for rate control in carefully selected arrhythmia or thyrotoxic cases.
Modern Alternatives: In many modern ICUs, esmolol (short-acting, beta-1 selective) or metoprolol are preferred for titratable beta-blockade; propranolol remains useful when its lipophilicity or T4-to-T3 conversion effects are desired.
Slow Administration Critical: Give IV propranolol slowly and in small increments with time to see effect; overshooting can produce profound bradycardia and hypotension that are hard to quickly reverse.
Chronic Indications: For chronic indications (migraine, portal hypertension, tremor), oral dosing strategies dominate; this reference focuses on short-term IV use in monitored settings.
Thyrotoxicosis Benefits: In thyrotoxicosis, oral or nasogastric propranolol (20–40 mg every 6 hours) is often preferred when feasible, due to more sustained control and impact on T4-to-T3 conversion.
First-Pass Metabolism: When transitioning from IV to oral propranolol, remember that oral bioavailability is lower and variable due to first-pass metabolism; start with modest oral doses and titrate to effect.
References
  • 1. Drugs.com. (2025). Propranolol dosage guide with precautions. https://www.drugs.com/dosage/propranolol.html
  • 2. U.S. Food and Drug Administration. (2024). Propranolol hydrochloride injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/016418s090lbl.pdf
  • 3. Shahrokhi, M., & Hamburg, N. M. (2023). Propranolol. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557801/
  • 4. DrugBank Online. (2024). Propranolol (DB00571). https://go.drugbank.com/drugs/DB00571
  • 5. Klein, I., & Ojamaa, K. (2001). Thyrotoxicosis and the heart. Endocrinology and Metabolism Clinics of North America, 30(2), 517–540. https://doi.org/10.1016/S0889-8529(05)70197-6
Back to Medication Index
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.